A Dose-Ranging Study of the Efficacy and Tolerability of Entecavir in Lamivudine-Refractory Chronic Hepatitis B Patients
- 1 October 2005
- journal article
- clinical trial
- Published by Elsevier in Gastroenterology
- Vol. 129 (4) , 1198-1209
- https://doi.org/10.1053/j.gastro.2005.06.055
Abstract
No abstract availableKeywords
This publication has 46 references indexed in Scilit:
- Clinical Emergence of Entecavir-Resistant Hepatitis B Virus Requires Additional Substitutions in Virus Already Resistant to LamivudineAntimicrobial Agents and Chemotherapy, 2004
- Lamivudine and Famciclovir resistant hepatitis B virus associated with fatal hepatic failureJournal of Clinical Virology, 2003
- Long‐Term Entecavir Treatment Results in Sustained Antiviral Efficacy and Prolonged Life Span in the Woodchuck Model of Chronic Hepatitis InfectionThe Journal of Infectious Diseases, 2001
- Serum alanine aminotransferase flares during interferon treatment of chronic hepatitis B: Is sustained clearance of HBV DNA dependent on levels of pretreatment viremia?Hepatology, 2001
- Fatal Submassive Hepatic Necrosis Associated with Tyrosine‐Methionine‐Aspartate‐Aspartate–Motif Mutation of Hepatitis B Virus after Long‐Term Lamivudine TherapyClinical Infectious Diseases, 2001
- Acute Exacerbation of Chronic Hepatitis B Virus Infection After Withdrawal of Lamivudine TherapyHepatology, 2000
- Lamivudine as Initial Treatment for Chronic Hepatitis B in the United StatesNew England Journal of Medicine, 1999
- Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapyHepatology, 1999
- Identification and characterization of mutations in hepatitis B virus resistant to lamivudineHepatology, 1998
- Lamivudine resistance inimmunocompetent chronic hepatitis BJournal of Hepatology, 1997